• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design
Conclusions ISCHEMIA will provide new scientific evidence regarding whether an invasive management strategy improves clinical outcomes when added to optimal medical therapy in patients with SIHD and moderate or severe ischemia.
Source: American Heart Journal - May 26, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death & amp; cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
Conclusions Using a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes. Graphical abstract
Source: American Heart Journal - June 13, 2018 Category: Cardiology Source Type: research

10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population
ConclusionsThe burden of AF among Asian patients is increasing. Although the overall risks of cardiovascular events and death following AF onset have decreased over a decade, the event rates are still high. Optimized management of any associated comorbidities should be part of the holistic management approach for patients with AF.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death & cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
ConclusionsUsing a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes.Graphical AbstractThe Atrial Fibrillation in the Emergency Room, part 2 (AFTER2) Study
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population
ConclusionsThe burden of AF among Asian patients is increasing. Although the overall risks of cardiovascular events and death following AF onset have decreased over a decade, the event rates are still high. Optimized management of any associated comorbidities should be part of the holistic management approach for patients with AF.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death & cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
ConclusionsUsing a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes.Graphical AbstractThe Atrial Fibrillation in the Emergency Room, part 2 (AFTER2) Study
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study
ConclusionsUsing a population-based sample, we derived and validated a tool that predicts the risk of early death and rehospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and rehospitalization for AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes.Graphical AbstractThe Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) Study.
Source: American Heart Journal - July 24, 2018 Category: Cardiology Source Type: research

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
Source: American Heart Journal - September 6, 2018 Category: Cardiology Source Type: research

Rationale and Design of the Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study
Publication date: Available online 29 September 2018Source: American Heart JournalAuthor(s): Aruna D. Pradhan, Nina P. Paynter, Brendan M. Everett, Robert J. Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R. Hiatt, Shun Ishibashi, Wolfgang Koenig, Børge G. Nordestgaard, Jean-Charles Fruchart, Peter Libby, Paul M RidkerAbstractObservational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective p...
Source: American Heart Journal - October 4, 2018 Category: Cardiology Source Type: research

Risk stratification and clinical outcomes after surgical pulmonary valve replacement
ConclusionPatients undergoing PVR at larger RV volumes had similar survival but more overall CAE. A larger study population with a longer follow-up will be required to determine if early PVR provides survival benefit in the long-term.
Source: American Heart Journal - October 4, 2018 Category: Cardiology Source Type: research

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease – Insights from the STABILITY trial
ConclusionThe primary outcome results of the STABILITY trial were consistent whether using investigator-reported or CEC-adjudicated events. The proportion of investigator-reported events confirmed by CEC varied by type of event. These results should help improve event identification in clinical trials to optimize ascertainment and adjudication.
Source: American Heart Journal - November 8, 2018 Category: Cardiology Source Type: research

Neck circumference and cardiovascular outcomes: Insights from the Jackson heart study
ConclusionsIn this large cohort of African American individuals, a larger NC was associated with increased risk for HF hospitalization following adjustment for age and sex, but this risk was not statistically significant after adjusting for other clinical variables. Although NC is not independently associated with increased risk for cardiovascular events, it may offer prognostic information particularly related to HF hospitalization.
Source: American Heart Journal - March 9, 2019 Category: Cardiology Source Type: research

Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design
ConclusionThis is the largest randomized trial to test if influenza vaccine compared to control reduces adverse vascular events in high risk individuals.Trial registration number:Clinicaltrials.govNCT02762851
Source: American Heart Journal - March 12, 2019 Category: Cardiology Source Type: research

Ticagrelor in patients with Heart failure after acute coronary syndromes – Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
ConclusionsIn patients with ACS, ticagrelor is more efficacious in protecting against new ischemic events and mortality than clopidogrel, irrespective of the presence of HF. There is no difference between ticagrelor or clopidogrel treatment in new-onset HF post-ACS.
Source: American Heart Journal - April 18, 2019 Category: Cardiology Source Type: research

Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
ConclusionsIn patients with ACS, ticagrelor is more efficacious in protecting against new ischemic events and mortality than clopidogrel irrespective of the presence of HF. There is no difference between ticagrelor or clopidogrel treatment in new-onset HF post-ACS.
Source: American Heart Journal - May 18, 2019 Category: Cardiology Source Type: research

Pages: 1  2  3  4  5  6  7  8